Sanofi (SNY) Enterprise Value (2009 - 2026)
Sanofi (SNY) posted Enterprise Value of -$7.0 billion for Q2 2026, little changed sequentially from -$6.9 billion in Q1 2026, and up 59.23% YoY from -$4.4 billion in Q2 2025.
Sanofi (SNY) Enterprise Value (2009 - 2026) Analysis & Trends
Sanofi has reported Enterprise Value for 18 years, with the latest figure at -$7.0 billion in Q2 2026.
- Quarterly Enterprise Value rose 59.23% year-over-year to -$7.0 billion in Q2 2026, while the trailing twelve-month figure through Jun 2026 was -$7.0 billion (up 59.23% YoY) and the FY2025 annual result came in at -$8.5 billion, down 12.5% from the prior year.
- Enterprise Value was little changed at -$7.0 billion in Q2 2026 per SNY's latest filing, from -$6.9 billion in the prior quarter.
- Over five years, Enterprise Value peaked at -$6.9 billion in Q1 2026 and troughed at -$17.1 billion in Q2 2025.
- A 5-year average of -$9.2 billion and a median of -$8.4 billion in 2025 frame the typical range for Enterprise Value.
- The sharpest annual moves came in 2025 and 2026: Enterprise Value slumped 144.45% in 2025, then soared 59.23% in 2026.
- Over 5 years, Enterprise Value stood at -$12.6 billion in 2022, then climbed by 28.4% to -$9.0 billion in 2023, then climbed by 16.13% to -$7.6 billion in 2024, then retreated by 12.5% to -$8.5 billion in 2025, then grew by 18.32% to -$7.0 billion in 2026.
- According to Business Quant data, Enterprise Value over the past three periods registered -$7.0 billion, -$6.9 billion, and -$8.5 billion for Q2 2026, Q1 2026, and Q4 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Enterprise Value (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 645.88 Bn | 625.12 Bn | 17.26 Bn | -20.76 Bn |
| 2 | AbbVie | 463.46 Bn | 456.89 Bn | 12.70 Bn | -6.52 Bn |
| 3 | Merck | 367.92 Bn | 360.78 Bn | 12.21 Bn | -7.09 Bn |
| 4 | Novartis Ag | 297.71 Bn | 290.02 Bn | 11.24 Bn | -7.69 Bn |
| 5 | Astrazeneca | 255.55 Bn | 250.65 Bn | 12.86 Bn | -4.90 Bn |
| 6 | Amgen | 234.52 Bn | 220.53 Bn | 7.24 Bn | -13.99 Bn |
| 7 | Gilead Sciences | 178.22 Bn | 175.04 Bn | 6.22 Bn | -3.26 Bn |
| 8 | Pfizer | 158.57 Bn | 146.88 Bn | 10.94 Bn | -11.40 Bn |
| 9 | Gsk | 105.32 Bn | 101.15 Bn | 8.24 Bn | -4.80 Bn |
| 10 | Sanofi | 54.20 Bn | 46.82 Bn | 10.79 Bn | -6.96 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -6.96 Bn |
| Mar 31, 2026 | -6.93 Bn |
| Dec 31, 2025 | -8.52 Bn |
| Sep 30, 2025 | -10.41 Bn |
| Jun 30, 2025 | -17.08 Bn |
| Mar 31, 2025 | -8.41 Bn |
| Dec 31, 2024 | -7.58 Bn |
| Jun 30, 2024 | -6.99 Bn |
| Mar 31, 2024 | -9.46 Bn |
| Dec 31, 2023 | -9.03 Bn |
| Jun 30, 2023 | -8.36 Bn |
| Dec 31, 2022 | -12.62 Bn |
| Jun 30, 2022 | -6.98 Bn |
| Dec 31, 2021 | -11.16 Bn |
| Jun 30, 2021 | -11.55 Bn |
| Dec 31, 2020 | -16.60 Bn |
| Jun 30, 2020 | -17.39 Bn |
| Dec 31, 2019 | -10.39 Bn |
| Jun 30, 2019 | -7.39 Bn |
| Dec 31, 2018 | -7.95 Bn |